P63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue

Journal of Thoracic Oncology

Volumn 6, Issue 3, 2011, Pages 473-481

  Iacono, Marco Lo ^a   Monica, Valentina ^a   Saviozzi, Silvia ^a   Ceppi, Paolo ^a   Bracco, Enrico ^a   Papotti, Mauro ^a   Scagliotti, Giorgio V ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Immunohistochemistry; Isoform; Molecular marker; Non small cell lung cancer; p63; p73; Quantitative PCR

Indexed keywords

ISOPROTEIN; PROTEIN P63; PROTEIN P73;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG TUMOR; MODULATION; MORPHOLOGY; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 79951770197     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820b86b0     Document Type: Article

References (27)

1. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006;13:962-972.
2. Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 2001;12:337-349. (Pubitemid 32685635)
3. Pietsch EC, Sykes SM, McMahon SB, et al. The p53 family and programmed cell death. Oncogene 2008;27:6507-6521.
4. Müller M, Schleithoff ES, Stremmel W, et al. One, two, three-p53, p63, 73 and chemosensitivity. Drug Resist Updat 2006;9:288-306.
5. Brambilla C, Fievet F, Jeanmart M, et al. Early detection of lung cancer: role of biomarkers. Eur Respir J Suppl 2003;39:36s- 44s. (Pubitemid 36125635)
6. Deyoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene 2007;26:5169-5183. (Pubitemid 47237632)
7. Melino G, Lu X, Gasco M, et al. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 2003;28:663-670. (Pubitemid 37500901)
8. Koga F, Kawakami S, Fujii Y, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003;9:5501-5507. (Pubitemid 37499468)
9. Urist MJ, Di Como CJ, Lu ML, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002;161:1199-1206.
10. Domínguez G, García JM, Peña C, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 2006; 4:805-815. (Pubitemid 46622048)
11. Wager M, Glhot J, Blanc JL, et al. Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients. Br J Cancer 2006;95:1062-1069. (Pubitemid 44608169)
12. Uramoto H, Sugio K, Oyama T, et al. Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 2004;10: 6905-6911. (Pubitemid 39383040)
13. Massion PP, Taflan PM, Jamshedur Rahman SM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003;63:7113-7121. (Pubitemid 37413448)
14. Reis-Filho JS, Simpson PT, Martins A, et al. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 2003;443:122-132. (Pubitemid 37056135)
15. Irwin MS, Kondo K, Marin MC, et al. Chemosensitivity linked to p73 function. Cancer Cell 2003;3:403-410. (Pubitemid 38340308)
16. Travis WD, Brambilla E, Müller-Hermelink HK, et al. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
17. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. New York: Wiley-Liss, 2002.
18. R: A Language and Environment for Statistical Computing [Computer Program]. Version 8.0. Vienna, Austria: R Foundation for Statistical Computing, 2009.
19. Buhlmann S, Pützer BM. DNp73 a matter of cancer: mechanisms and clinical implications. Biochim Biophys Acta 2008;1785:207-216.
20. Marchini S, Marabese M, Marrazzo E, et al. DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann Oncol 2008;19: 501-507. (Pubitemid 351325671)
21. Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep 2008;9:1087-1093.
22. Tannapfel A, John K, Mise N, et al. Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73. Carcinogenesis 2008;29:211-218. (Pubitemid 351201761)
23. Bozzetti C, Nizzoli R, Musolino A, et al. p73 and p53 pathway in human breast cancers. J Clin Oncol 2007;25:1451-1453; author reply 1453-1454. (Pubitemid 46706904)
24. Inoue T, Stuart J, Leno R, et al. Nuclear import and export signals in control of the p53-related protein p73. J Biol Chem 2002;277:15053-15060. (Pubitemid 34952582)
25. Marrazzo E, Marchini S, Tavecchio M, et al. The expression of the DeltaNp73beta isoform of p73 leads to tetraploidy. Eur J Cancer 2009;45:443-453.
26. Rocco JW, Leong CO, Kuperwasser N, et al. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006;9:45-56. (Pubitemid 43069510)
27. Leong CO, Vidnovic N, DeYoung MP, et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007;117:1370-1380. (Pubitemid 46718425)